Skip to main content

Novartis India Limited (NOVARTIND.NS)

National Stock Exchange of India Healthcare Drug Manufacturers - Specialty & GenericView data quality →
61.1Fair

ValueMarkers Composite Index

Top 82%#8,062 of 44,707

DCF data not available

Piotroski
7/9
Strong
Beneish
-2.39
Low Risk
Altman
9.19
Safe
DCF Value
-
N/A
ROIC
9.5%
Adequate
P/E
25.7
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Novartis India Limited (NOVARTIND.NS) — VMCI valuation read

Novartis India Limited (NOVARTIND.NS) carries a VMCI composite of 61/100, 11 points above the Healthcare sector median of 50. Among mid-cap names, that gap places NOVARTIND.NS in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The NOVARTIND.NS insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads NOVARTIND.NS trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -0.2x leaves covenant headroom, the line to track on Novartis India Limited's next 10-Q.

NOVARTIND.NS rose 1.0% over the trailing 7 days, with a +0.3% read on a 30-day basis.

Novartis India Limited operates as a healthcare company in India. It offers pharmaceutical products in the areas of bone and pain, calcium portfolio, gynecology, and neurosciences, as well as generics products in the areas of gynecology, anti-TB, and anti-infectives. The company provides central nervous system products under the Tegrital and Exelon brands; pain and inflammation products under the Voveran brand; and transplantation/immunology products under the Simulect, Certican, Myfortic, and Sandimmun Neoral brands. The company was incorporated in 1947 and is headquartered in Mumbai, India. Novartis India Limited is a subsidiary of Novartis AG.

CEO: Vasant Narasimhan62 employeesINwww.novartis.in

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in NOVARTIND.NS’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.